Neuroprotective and Cognitive Enhancers
Cognitive dysfunction (“brain fog”) is among the most disabling symptoms in ME/CFS. This section reviews agents that may support cognitive function through neuroprotection, enhanced cerebral blood flow, or neurotransmitter modulation.
1 Ginkgo biloba (EGb 761)
Mechanism. Ginkgo biloba extract (standardized as EGb 761) contains flavonoid glycosides and terpene lactones with multiple neurologically relevant actions:
- Cerebral blood flow enhancement: Increases microvascular perfusion through vasodilatory and hemorheological effects
- Antioxidant activity: Scavenges free radicals and reduces lipid peroxidation in neural tissue
- Platelet-activating factor (PAF) antagonism: Terpene lactones (ginkgolides) inhibit PAF, reducing neuroinflammation
- Mitochondrial protection: May support mitochondrial function under oxidative stress
- Neurotransmitter modulation: Enhances cholinergic, dopaminergic, and noradrenergic transmission
Relevance to ME/CFS. ME/CFS involves documented cerebral hypoperfusion (reduced blood flow to brain), oxidative stress, and cognitive impairment. Ginkgo’s multi-target mechanism addresses several of these features:
- Cerebral blood flow enhancement may improve cognitive symptoms related to hypoperfusion
- PAF antagonism may reduce neuroinflammation, particularly relevant for MCAS subset
- Antioxidant effects support compromised cellular defenses
Evidence Base.
- Cognitive impairment: Meta-analyses demonstrate modest cognitive benefits in dementia and age-related cognitive decline (Gauthier and Schlaefke 2014) (Yuan et al. 2017)
- Cerebral insufficiency: German Commission E approved for cerebral insufficiency with symptoms including difficulty concentrating, memory deficits, and fatigue (German Commission E 1994)
- ME/CFS-specific: No randomized controlled trials in ME/CFS specifically; evidence extrapolated from related conditions
- Fibromyalgia: Small studies suggest potential benefit for cognitive symptoms, but evidence is limited
Dosing.
- Standard dose: 120–240 mg daily of standardized extract (EGb 761 or equivalent)
- Typical products: Cerebokan, Ginkobil, Tebonin (all standardized to 24% flavonoid glycosides, 6% terpene lactones)
- Division: Usually split into 2–3 doses daily (e.g., 80 mg three times daily)
- Onset: Effects may require 4–6 weeks of consistent use
Safety Considerations.
- Bleeding risk: Ginkgo has antiplatelet effects; caution with anticoagulants (warfarin), antiplatelet agents (aspirin, clopidogrel), and before surgery
- Drug interactions: May affect CYP enzyme metabolism; potential interactions with SSRIs (serotonin syndrome risk), anticonvulsants
- Seizure threshold: Theoretical concern for lowering seizure threshold (ginkgotoxin in impure preparations); use only standardized extracts
- Gastrointestinal: Mild GI upset, headache in some patients
- Quality control: Use standardized pharmaceutical-grade extracts; avoid unprocessed ginkgo seeds (toxic)
Ginkgo biloba may provide modest support for cognitive symptoms in ME/CFS through enhanced cerebral blood flow and antioxidant effects. Use standardized extract (EGb 761 equivalent) 120–240 mg daily for minimum 6 weeks to assess response. Caution: Review bleeding risk and drug interactions before initiating. Not a substitute for pacing—cognitive energy still limited even with pharmaceutical support.
Energy Profile. Category B (energy-neutral). Standardized herbal extract with minimal metabolic processing demands. Improved cerebral blood flow may enhance brain energy substrate delivery, providing an indirect positive effect on cognitive energy availability. Caution: CYP enzyme interactions mean Ginkgo can alter the metabolism of co-administered medications, potentially shifting their energy classification; review the full medication list before initiating.
2 Ginkgo biloba (EGb 761)
Ginkgo biloba may provide modest support for cognitive symptoms in ME/CFS through enhanced cerebral blood flow and antioxidant effects. Use standardized extract (EGb 761 equivalent) 120–240 mg daily for minimum 6 weeks to assess response. Caution: Review bleeding risk and drug interactions before initiating. Not a substitute for pacing—cognitive energy still limited even with pharmaceutical support.
3 Dopaminergic Augmentation (L-DOPA, MAO-B Inhibitors, Dopamine Agonists)
All agents discussed in this section are experimental for ME/CFS. None has been tested in a single ME/CFS or long COVID trial. These are proposed clinical trial designs, not treatment recommendations. Do not initiate any of these agents for ME/CFS outside a registered clinical trial protocol with appropriate safety monitoring. Patients should not seek these medications independently — they carry risks of sudden hypotension, serotonin syndrome (fatal), and impulse control disorders. See Warning Safety Assessment for Dopaminergic Agents in ME/CFS for a full safety assessment.
Certainty: 0.25 (extrapolation from long COVID VMAT2 PET data to ME/CFS; see Observation Striatal Dopaminergic Terminal Loss Quantified by VMAT2 PET in Long COVID). Liu et al. (2026) demonstrated a 16–20% reduction in striatal VMAT2 binding — a validated marker of dopaminergic terminal integrity — in 24 long COVID patients using (+)[“11C”]DTBZ PET, with reductions concentrated in ventral striatum (apathy, r=−0.54), dorsal putamen (motor slowing, r=0.51), and dorsal caudate (memory decline, r=0.58) (Liu et al. 2026). Multi-modal imaging of the same Toronto patient sample showed co-occurring elevated TSPO PET (microglial activation) (Braga et al. 2023) and MAO-B PET (astrogliosis) (Braga et al. 2025) in the same striatal regions — an association within one cohort, not independently replicated convergence. Postmortem evidence confirms that SARS-CoV-2 can directly infect dopaminergic neurons via ACE2 receptors and induce cellular senescence (Yang et al. 2024).
This evidence base supports a testable hypothesis: dopaminergic augmentation may improve apathy, motor slowing, and cognitive symptoms in a subset of post-infectious ME/CFS patients whose phenotype mirrors the apathy-predominant long COVID subgroup studied by Liu et al. However, this hypothesis carries major caveats. Zero VMAT2 PET data exist in ME/CFS — the entire argument rests on cross-condition inference from long COVID. Aregawi et al. (2026) found normal CSF dopamine pathway indices (DA + DOPAC + HVA) in PI-ME/CFS, with selective deficiency in the noradrenergic pathway (Aregawi et al. 2026). The normal CSF DA finding is unexpected under a VMAT2-deficiency model — VMAT2 transports both DA and NE, and reduced transporter capacity should affect both monoamines. The dissociation (normal DA, low NE) either means VMAT2 loss does not generalize to PI-ME/CFS, or a compensation mechanism (upregulated DA synthesis per terminal) maintains normal output despite fewer terminals. The prior probability favours non-generalization until simultaneous CSF+PET measurement demonstrates otherwise.
Possible therapeutic agents (proposed trial framework — NOT treatment recommendations):
- L-DOPA / Carbidopa. Dopamine precursor. Proposed trial dosing: 1/4 tablet of 25/100 mg BID, titrated slowly over weeks. Augments tonic and phasic dopamine release from surviving terminals. Risks: nausea, orthostatic hypotension — L-DOPA should be considered relatively contraindicated in any patient with orthostatic intolerance unless orthostatic vitals have been documented at baseline and each dose escalation, and a plan for managing acute OH exists. L-DOPA is a research-stage proposal for ME/CFS. Do not prescribe outside a trial.
- MAO-B Inhibitors. Selegiline and rasagiline prevent dopamine degradation. May be relevant if astrogliosis-driven MAO-B hyperactivity contributes to accelerated turnover. Proposed trial dosing: selegiline 1.25–2.5 mg/day (1/4–1/2 of Parkinson’s dose); rasagiline 0.25 mg/day (1/2 tablet of 0.5 mg — 0.1 mg dosing is not achievable with commercial tablets). Meyer (the senior author of Liu et al. 2026) has filed a patent for rasagiline + tyramine for long COVID — readers should evaluate the evidence with awareness of this commercial interest. Risks: serotonin syndrome with SSRIs/SNRIs; washout required (14 days off MAOI before starting SSRI, and 2 weeks fluoxetine / 5 half-lives other SSRIs before starting MAOI — this is a sequential trial, not a switch). Tyramine restriction is mandatory; transdermal selegiline at 6 mg/24h reduces but does not eliminate dietary risk (aged cheese, cured meats, tap beer remain dangerous). Do not prescribe outside a trial.
- Dopamine Agonists. Pramipexole (D2/D3 agonist) stimulates postsynaptic receptors independently of terminal integrity. Proposed trial dose range: 0.125–0.5 mg/day (RLS starting dose), with the effective dose for ME/CFS apathy entirely unknown. Risks: impulse control disorders (black box warning — 14–17% incidence in Parkinson’s populations; risk in bedbound ME/CFS patients is unknown but likely similar given full access to online gambling, shopping, and compulsive internet use). Screen at baseline and monthly with QUIP-RS. Nausea, somnolence, orthostatic hypotension. Dopamine agonist withdrawal syndrome (DAWS — 10–20% incidence, mimics ME/CFS crash) requires a slow taper if discontinuing. Do not prescribe outside a trial.
- Low-Dose Aripiprazole (LDA). Already in off-label ME/CFS use (Section on Low-Dose Aripiprazole, this chapter). LDA is a partial D2/D3 agonist with 5-HT1A partial agonism — it modulates rather than augments dopamine signaling and has independent anti-inflammatory (microglial) effects. Unlike the agents above, LDA has existing ME/CFS safety data, making it the lowest-barrier candidate for a stratified trial. However, LDA trials in ME/CFS have not stratified patients by apathy or motor-slowing phenotype.
Consequence: If validated by ME/CFS VMAT2 PET and then by targeted trials, this framework would move treatment from empiricism to mechanism-matching for patients with a confirmed dopaminergic phenotype. In the absence of ME/CFS data, all agents above are experimental and should not be prescribed. None of these agents has been studied in the context of severe ME/CFS medication hypersensitivity; if a trial were conducted, starting doses should be 1/4 to 1/10 of Parkinson’s standard with weekly orthostatic monitoring and impulse-control screening.
Limitations. No VMAT2 PET, DAT PET, or DA augmentation trial in ME/CFS. The Liu 2026 sample (young, n=24, apathy-enriched by inclusion criteria, single tertiary clinic) may not represent the broader ME/CFS population — the VMAT2-apathy correlation (r=−0.54) was found in a cohort where every patient had apathy. The normal CSF DA finding (Aregawi 2026) in the population that matters most (PI-ME/CFS) is a stronger constraint on the model than currently reflected. Peripheral DA metabolites showed no correlation with VMAT2 binding, meaning VMAT2 PET — a research-only imaging modality — would be required to identify putative DA-deficient patients — no blood test can substitute. The PD comparison (16–20% VMAT2 reduction is below the 50–60% motor-symptom threshold) cautions against over-interpreting the clinical significance of the binding reduction.
Severity applicability: Unknown. No DA augmentation data in any ME/CFS severity level. Do not initiate dopaminergic augmentation in severe or very severe ME/CFS (bedbound patients) outside an inpatient clinical trial with continuous monitoring.
Origin: literature inference (Liu 2026).
Falsifiable predictions. (a) VMAT2 PET in apathy-predominant post-infectious ME/CFS (n≥20 per trigger) should show reduced binding in SARS-CoV-2-triggered but not EBV/other-triggered subgroups. (b) L-DOPA 25/100 mg BID should improve Apathy Evaluation Scale by ≥3 points over placebo in VMAT2-confirmed patients in a crossover RCT (n≥30). (c) Baseline VMAT2 binding should predict treatment response (r > 0.4). Falsified if VMAT2 PET is normal in ME/CFS regardless of trigger; if L-DOPA fails to improve apathy in VMAT2-low patients; or if VMAT2 binding does not predict response.
Experimental status. None of these agents has been studied in ME/CFS. All information below is drawn from Parkinson’s disease, depression, and RLS populations and may not generalise to ME/CFS patients with medication hypersensitivity, polypharmacy, and orthostatic intolerance.
Orthostatic intolerance. L-DOPA and dopamine agonists can cause or worsen orthostatic hypotension. POTS/OI is present in ~60–80% of ME/CFS patients. Before any trial of a dopaminergic agent: (a) document orthostatic blood pressure and heart rate supine, at 1 min standing, and at 3 min standing; (b) repeat at each dose escalation; (c) have a plan for management of acute OH (hold dose, increase fluids/salt, supine positioning). These agents are relatively contraindicated in patients with OI unless these safeguards are in place.
Polypharmacy interactions (common in ME/CFS). Fludrocortisone: unpredictable BP interaction with L-DOPA’s OH effect. Midodrine (α1-agonist): direct pharmacological opposition (L-DOPA lowers BP, midodrine raises it — net unpredictable). Beta-blockers (propranolol, atenolol): mask compensatory tachycardia from OH → risk of unrecognised hypotension. Pyridostigmine (Mestinon): cholinergic-dopaminergic balance interaction with L-DOPA-induced dyskinesia (theoretical, no ME/CFS data). LDN: both agents modulate reward circuitry independently; additive effects untested.
Serotonin syndrome. MAO-B inhibitors + any serotonergic agent (SSRI, SNRI, TCA, 5-HTP, tramadol, triptans) can be fatal. Washout required in BOTH directions: 14 days off MAOI before starting SSRI; 2 weeks fluoxetine / 5 half-lives other SSRIs before starting MAOI. This is a sequential trial separated by a washout, not a switch. Provide counseling: do not discontinue an antidepressant and start an MAOI without medical supervision and adequate washout.
Hypertensive crisis. MAOIs + tyramine-rich foods (aged cheese, cured meats, fermented foods, tap beer) → hypertensive crisis. Dietary counseling is mandatory. Transdermal selegiline at 6 mg/24h reduces but does not eliminate dietary risk — patients must still avoid concentrated tyramine sources. At >6 mg/24h, restrictions are identical to oral MAOIs. Provide a written dietary guide.
Impulse control disorders. Dopamine agonists carry a black-box warning. Parkinson’s incidence is 14–17%. Risk in ME/CFS is unknown — the conclusion that reduced mobility may lower risk is incorrect (online gambling, internet shopping, and compulsive internet use are fully accessible from bed). Screen every patient at baseline and at each follow-up with QUIP-RS. Discontinue immediately if impulse control symptoms emerge.
Dopamine agonist withdrawal syndrome (DAWS). Affects 10–20% of patients discontinuing dopamine agonists. Symptoms (anxiety, panic, depression, pain, orthostatic intolerance, fatigue) mimic an ME/CFS crash. If a trial participant worsens on agonist discontinuation, DAWS must be excluded before attributing deterioration to disease progression. Taper slowly; do not stop abruptly.
Monitoring framework (required for any trial). Baseline orthostatic vitals; weekly for first 4 weeks of titration. Baseline QUIP-RS impulse control screening, monthly thereafter. PEM diary — discontinue if PEM frequency or severity increases (L-DOPA may mask fatigue → overexertion → crash). No improvement at 8 weeks → discontinue. Baseline EKG (dopamine agonists have been associated with QT prolongation).
Severe/very severe patients. Do not initiate dopaminergic augmentation in severe or very severe ME/CFS (bedbound) outside an inpatient clinical trial with continuous monitoring. These patients cannot report symptomatic OH or impulse control symptoms promptly, and supine positioning limits compensatory options for hypotension.
Pregnancy/lactation. No pregnancy or lactation safety data. All dopaminergic agents cross the placenta. Do not prescribe in pregnancy or breastfeeding.
Patient warning. This information is for physician guidance only. Dopaminergic agents are experimental for ME/CFS. Patients should not attempt to obtain these medications independently.
Ginkgo biloba may provide modest support for cognitive symptoms in ME/CFS through enhanced cerebral blood flow and antioxidant effects. Use standardized extract (EGb 761 equivalent) 120–240 mg daily for minimum 6 weeks to assess response. Caution: Review bleeding risk and drug interactions before initiating. Not a substitute for pacing—cognitive energy still limited even with pharmaceutical support.